Online inquiry

IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1441MR)

This product GTTS-WQ1441MR is a type of mRNA modified with 5-Methoxy-UTP, which ecodes the monoclonal antibody that targets Aβ15-42 gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Corynebacterium diphtheriae; Homo sapiens
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Aβ15-42, ACC-001(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ1441MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ1636MR IVTScrip™ mRNA-Anti-F10&F9, ACE-910(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA ACE-910
GTTS-WQ14540MR IVTScrip™ mRNA-Anti-IL13&IL4, SAR156597(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SAR156597
GTTS-WQ9141MR IVTScrip™ mRNA-Anti-EGFR, IMGN-289(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA IMGN-289
GTTS-WQ3702MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ3696MR IVTScrip™ mRNA-Anti-MSLN, BAY 2287409(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 2287409
GTTS-WQ3030MR IVTScrip™ mRNA-Anti-ITGA4&ITGB7&ITGAE, Anti-Beta7(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA Anti-Beta7
GTTS-WQ5186MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CAT-354
GTTS-WQ9467MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA IPH-5401
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW